Several preclinical models and clinical trials demonstrated the ability of IL-15 to counteract HCC-induced NK dysfunction, and these findings make it a promising cytokine for cancer immunotherapy [27,28,29,30,31,32]. This evidence concerns the gene IL15 and cancer.